# Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

> **NCT01073891** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Moxifloxacin (Avelox, BAY12-8039)
- **DRUG:** Moxifloxacin (BAY12-8039)
- **DRUG:** Moxifloxacin (BAY12-8039)

## Key facts

- **NCT ID:** NCT01073891
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-11
- **Final completion:** 2011-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073891, "Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01073891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*